TwinStrand DuplexSeq measuring MRD in AML

In the News

Life Science Washington - April 20, 2022

Our CEO, Jesse Salk MD, PhD will be speaking at the Life Sciences Innovation Northwest (LSINW) 2022 Convention during the Research Tools & Medical Device session.

Wednesday, April 20th, 2022 – 2:46pm PST

TwinStrand Biosciences - February 24, 2022

This year we were proud to sponsor the scientific workshop Applying Molecular Biology & Genetic Toxicology Methods to Improve Risk Assessment and Guide Risk Management Decisions for Cancer in Firefighters at the 2022 National Cancer Fire Symposium, hosted by the Firefighter Cancer Initiative (FCI).

FNIH - February 11, 2022

TwinStrand Biosciences, Inc. was selected to join the FNIH Biomarkers Consortium Project aiming to establish new methods for detecting measurable residual disease (MRD) in Acute Myeloid Leukemia (AML). See the FNIH announcement here.